Skip to main content

Advertisement

Table 4 Subgroup analyses of relationship between adiponectin levels and presence of metabolic syndrome

From: Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study

  Odds ratio (95% confidence interval)
DM Non-DM
Total HTN GN PKD
Crude 0.964 (0.943–0.984) 0.951 (0.935–0.967) 0.941 (0.912–0.971) 0.955 (0.931–0.979) 0.944 (0.904–0.987)
Model 1 0.973 (0.949–0.997) 0.969 (0.951–0.988) 0.949 (0.916–0.984) 0.980 (0.952–1.009) 0.954 (0.907–1.004)
Model 2 0.952 (0.923–0.981) 0.957 (0.935–0.980) 0.944 (0.905–0.985) 0.949 (0.913–0.987) 0.962 (0.911–1.016)
Model 3 0.946 (0.913–0.980) 0.957 (0.932–0.983) 0.950 (0.901–1.003) 0.942 (0.900–0.986) 0.950 (0.899–1.004)
Model 4 0.933 (0.898–0.970) 0.959 (0.932–0.986) 0.939 (0.885–0.996) 0.942 (0.896–0.990) 0.969 (0.913–1.028)
  1. Adiponectin 1 μg/mL increase, subgroup analysis was performed according to the cause of chronic kidney disease
  2. Model 1: adjusted for age, gender, smoking status, and body mass index
  3. Model 2: adjusted for model 1 + hemoglobin, serum albumin, uric acid, phosphate, and parathyroid hormone
  4. Model 3: adjusted for model 2 + hs-CRP, urine albumin-to-creatinine ratio, and eGFR
  5. Model 4: adjusted for model 3 + coronary artery disease, cerebrovascular disease, ARB, diuretics, statin, ezetimibe, and fibrate
  6. DM diabetic mellitus, HTN hypertension, GN glomerulonephritis, PKD polycystic kidney disease, hs-CRP high sensitivity C-reactive protein, eGFR estimated glomerular filtration rate, ARB angiotensin II receptor blocker